Evropska unija -
slovenščina -
EMA (European Medicines Agency)
busilvex
pierre fabre medicament - busulfan - hematopoetična presaditev izvornih celic - antineoplastična sredstva - busilvex sledi ciklofosfamid (bucy2) je navedena kot kondicioniranje zdravljenje pred konvencionalne krvotvornih matičnih celic presaditev (hpct) pri odraslih bolnikih, ko kombinacija se šteje na voljo možnost. busilvex naslednje fludarabine (fb) je označena kot naprava za zdravljenje pred haematopoietic progenitor cell presaditev (hpct) pri odraslih bolniki, ki so kandidati za zmanjšane intenzivnosti naprava (ric) režim. busilvex sledi ciklofosfamid (bucy4) ali melphalan (bumel) je označena kot naprava za zdravljenje pred konvencionalnimi haematopoietic progenitor cell presaditev v pediatričnih bolnikih.
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
botox 100 allerganovih enot prašek za pripravo raztopine za injiciranje
sanolabor, d.d. - prašek za raztopino za injiciranje - botulinski toksin
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
lenalidomide krka (previously lenalidomide krka d.d. novo mesto)
krka, d.d., novo mesto - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imunosupresivi - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indiciran za zdravljenje odraslih bolnikov s predhodno nezdravljenih več plazmocitom, ki niso primerni za presaditev. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 in 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indiciran za zdravljenje odraslih bolnikov s predhodno nezdravljenih več plazmocitom, ki niso primerni za presaditev. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 in 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
ensure čokolada 250 ml pločevinka
živilo za posebne zdravstvene namene - peroralna suspenzija - živilo za posebne zdravstvene namene 250 ml / 1 pločevinka - maščobe, ogljikovi hidrati, proteini, minerali in vitamini, kombinacije
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
ensure plus jagoda 220 ml tetrapak
živilo za posebne zdravstvene namene - peroralna suspenzija - živilo za posebne zdravstvene namene 220 ml / 1 tetrapak - maščobe, ogljikovi hidrati, proteini, minerali in vitamini, kombinacije
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
ensure 2 cal vanilija 200 ml plastenka
peroralna suspenzija - maščobe, ogljikovi hidrati, proteini, minerali in vitamini, kombinacije
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
ensure plus banana 220 ml tetrapak
živilo za posebne zdravstvene namene - peroralna suspenzija - živilo za posebne zdravstvene namene 220 ml / 1 tetrapak - maščobe, ogljikovi hidrati, proteini, minerali in vitamini, kombinacije
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
ensure plus čokolada 220 ml tetrapak
živilo za posebne zdravstvene namene - peroralna suspenzija - živilo za posebne zdravstvene namene 220 ml / 1 tetrapak - maščobe, ogljikovi hidrati, proteini, minerali in vitamini, kombinacije
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
ensure plus vanilija 220 ml tetrapak
živilo za posebne zdravstvene namene - peroralna suspenzija - živilo za posebne zdravstvene namene 220 ml / 1 tetrapak - maščobe, ogljikovi hidrati, proteini, minerali in vitamini, kombinacije
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
glucerna sr, okus vanilije
peroralna suspenzija - maščobe, ogljikovi hidrati, proteini, minerali in vitamini, kombinacije